Curriculum Vitae

PERSONAL INFORMATION

Name	**Ying-Jui Ho 何應瑞**	**Dender**	Male	Age	
Nationality	Republic of China	**ID no.**			
City of born	Hualien, Taiwan	**Birth date**			
Address	No.110, Sec.1, Jianguo N. Rd., Taichung City 402, Taiwan, ROC				
E-mail	yjho@csmu.edu.tw; joshuayjho@gmail.com				
Tel. No.	+886-4-24730022 ext. 11858	**Fax no.**	+886-4-23248191		
Website	http://w3.csmu.edu.tw/~yjho/				
Mobile phone					

EDUCATION

Degree	School	Institute	Major	Date
Ph.D.	National Taiwan University	Institute of Physiology	Behavioral Neuroscience	1994/9 ~ 2002/5
	Thesis: The Role of Glutamatergic System in the Behavior Expression in Olfactory Bulbectomized Rats			Advisor: Dr. Yuan-Feen Tsai
M.S.	National Defense Medical Center	Institute of Physiology	Psychopharmacology and Neuroscience	1992/9 ~ 1994/7
	Thesis: Effects of excitatory amino acid and antipsychotics, haloperidal and amperozide, on dopamine transmission in rat's nucleus accumbens and striatum			Advisor: Dr. Che-Se Tung
B.S.	Kaohsiung Medical University	Department of Pharmacy	Pharmacy	1986/9 ~ 1990/6

PROFESSIONAL DISCIPLINE

Physiology, Pharmacology, Neuroscience, Neuropharmacology, Psychology, Biopsychology Neurodegeneration, Parkinson's disease, Dementia with Lewy bodies, Animal Study, Behavioral science, Cognitive function

Recent Research

A **phase 2 clinical trial** approved by US and Taiwan FDAs: applying ceftriaxone on neurodegeneration and dementia in Parkinson's disease

頭孢曲松治療巴金森氏症失智臨床試驗: Title: To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia。Trial No.: BRICEFA20170414; Website: https://clinicaltrials.gov/ct2/results?cond=&term=BRICEFA20170414&cntry=&state=&city=&dist=&Search=Search

Ceftriaxone is developed for the new indication to treat Parkinson's disease dementia (PDD). Ceftriaxone is the drug substance of Rocephin® approved by FDA in 1984 as a cephalosporin antibiotic to function as anti-bacterial infection. Ceftriaxone is a β-lactam antibiotic for treating respiratory tract infection, urinary tract infection, bacterial septicemia, and meningitis (Congeniet al., 1984). It has been reported that ceftriaxone upregulated expression of glutamate transporter-1(GLT-1) (Rothsteinet al.,2005), and several subsequent studies demonstrated the antiexcitotoxic potential of this compound (Chu et al.,2007).Neuroprotective effects of ceftriaxone have been demonstrated following 5 days of pretreatment with ceftriaxone(200 mg/kg/day)in the *in vitro* models of stroke (Lipskiet al., 2007). Treatment with ceftriaxone(200 mg/kg/day) for 7 or 14 days during hypoxic exposure was found to increase GLT-1 expression, resulting in sequestration of excess glutamate into glial cells, protection of neurons from excitotoxicity, and improved spatial memory retrieval (Hotaet al.,2009).However, nothing is known about the effects of ceftriaxone on cognitive behavior and neurodegeneration in Parkinson's disease(PD)patients.

Since ceftriaxone increases GLT-1 expression and reuptake of released glutamate may thus reduce excitotoxicity, it may be useful for treating PD symptoms. Ceftriaxone was used to conduct in several nonclinical pharmacological studies to show the effects of ceftriaxone on working memory, object recognition, and neuroprotection in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD rat model, which demonstrated that ceftriaxone inhibited MPTP lesion-induced dopaminergic degeneration in the nigrostriatal system, microglial activation in the substantia nigra pars compacta (SNc), and cell loss in the hippocampal CA1 area. These results demonstrate that ceftriaxone prevents loss of neurogenesis in the brain of PD rats.

Clinical program: A randomized, double-blinded, Phase II trial is designed to investigate the safety and efficacy profiles of ceftriaxone in PDD patients.

The present study includes primary and secondary study objectives. The primary objective is to evaluate the improvement of cognitive function in PDD patients with ceftriaxone administration. The secondary objectives are to evaluate the efficacy and safety profiles in PDD patients with ceftriaxone administration. The study will be enrolled in approximate 106 patients to achieve at least 84 evaluable patients. Eligible subjects will be randomized to receive either ceftriaxone or placebo in a 1:1 ratio. Patients in the investigational product group will receive 1g/day of ceftriaxone reconstituted in lidocaine; while patients with placebo treatment will receive the same volume of lidocaine injection. Both groups will be administered via intramuscular (IM) injection for 3 doses every cycle (2 weekly cycle), for a total of 16 cycles.

For primary endpoint, comparison of the treatment difference in mean net change in Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog)score with time course will be evaluated. For secondary endpoints, the efficacy profile of ceftriaxone will be assessed by the changes of Unified Parkinson's Disease Rating Scale (UPDRS), Judgment of Line Orientation score, Mini Mental

State Examination, Clinical Dementia Rating Scale, Color Trail test scores, Tc-99m TRODAT SPECT and MRI images changes as well as the overall evaluation of Alzheimer's Disease Cooperative Study-Clinician's Global Impression of Change(ADCS-CGIC) score from baseline at week 16 and 32 visits. The baseline of each efficacy factors will be evaluated on Day 1 before dosing.

PROFESSIONAL EXPERIENCE

Department /	Institution	Position	Date
Department of Psychology 心理學系	Chung Shan Medical University 中山醫學大學	Professor 教授	2011/08 ~ present
Russian International Affairs Council (RIAC)俄羅斯國際事務部	the Review Board of the Russian Science Foundation (RSF)俄國科學基金會	審查委員	2019/04 ~迄今
南投縣政府 防毒委員			2016.08.01-2018.07.31
台中市政府 防毒委員			2017.01.01-2018.12.31
BrainX Corporation		Founding Shareholder	2016.07.06~
The Chinese Physiological Society 中國生理學會		Member of the Council 理事	2016/04/05 ~
瑞金抗齡基金會		董事	2017.01.01 ~
The Chinese Physiological Society 中國生理學會		Executive Secretary 秘書長	2012/03/01 ~ 2016/04/01
Student Affairs 學務處	Chung Shan Medical University 中山醫學大學	Dean 學務長	2012.08.01~ 2014.07.31
中山醫學大學 Chung Shan Medical University	教師會 Teacher association	理事長 Director-General	2012/01/01 ~ 2012/07/31
Chung Shan Medical University Hospital 中山醫院	Human Subject Research Ethics Committee/ IRB 人體研究委員會	Independent Expert Consultant 獨立諮詢委員	2011/08/01 ~ present
Taiwan Neuromodulation Society 台灣神經調節學會		Member of the Council 理事	2007/12 ~ present
Dept. Psychopharmacology 藥理學科	Central Institute of Mental Health, Germany 德國心智健康研究院	Visiting Fellow 訪問學者	2007/06/30 ~ 07/11
Division of Extracurricular Activities 課外活動組	Office of Student Affairs, Chung Shan Medical University 中山醫學大學	Chair 主任	2006/03 ~ 2008/03
Department of Psychology 心理學系	Chung Shan Medical University 中山醫學大學	Associate Professor 副教授	2005/08 ~ 2011/07/31

Department of Psychology 心理學系	Chung Shan Medical University 中山醫學大學	Assistant Professor 助理教授	2002/08 ~ 2005/07/31
Experimental and Physiological Psychology 實驗與生理心理學系	Philipps University of Marburg, Germany 德國 Marburg 大學	Visiting Scholar 訪問學者	2001/03 ~ 2002/02
Chang Gung Nursing Junior College 長庚護專		Lecturer 兼任講師	2000/09 ~ 2001/01
Tri-Service General Hospital 三軍總醫院		Pharmacist 藥劑師	1993/01 ~ 1993/06
Chinese Air Force 空軍		Commissioned Lieutenant 少尉軍官	1990/07 ~ 1992/05

PUBLICATIONS

(A) Referred Paper in English

1. Cheng SM, **YJ Ho**, SH Yu, YF Liu, YY Lin, CY Huang, HC Ou, HL Hung, SD Lee. Anti-apototic effects of diosgenin in D-galactose-indiced aging brain. ***Am J Chin Med*** 48(2): 1-6, 2020. **(SCI)**
2. Liao WC, CK Liao, TJ Tseng, **YJ Ho**, YR Chen, KH Lin, TJ Lai, CT Lan, KC Wei, CH Liu. Chondroitin sulfate synthase 1 enhances proliferation of glioblastoma by modulating PDGFRA stability. ***Oncogenesis*** 9: 9, 2020. **(SCI)**
3. Liu CH, HM Chang, YS Yang, YT Lin, **YJ Ho**, TJ Tseng, CT Lan, ST Li, WC Liao.. Melatonin promotes nerve regeneration following end-to-side neurorrhaphy by accelerating cytoskeletal remodeling via the melatonin receptor-dependent pathway. ***Neurosci*** (inpress, 2020) **(SCI)**
4. Chang CC, TC Lin, HL Ho HL, CY Kuo, HH Li, TA Korolenko, WJ Chen, TJ Lai, **YJ Ho**, CL Lin, GLP-1 Analogue Liraglutide Attenuates Mutant Huntingtin-Induced Neurotoxicity by Restoration of Neuronal Insulin Signaling." ***Int J Mol Sci*** 19(9), 2018. **(SCI)**
5. **Ho YJ*** MS Shen, CH Tai, HH Li, JH Chen WC Liao, PY Chiu, IY Lee, CL Lin*, CS Hung*. Use of ceftriaxone in treating cognitive and neuronal deficits associated with dementia with Lewy bodies. ***Frontiers in Neuroscience*** 13: 507, 2019. DOI: 10.3389/fnins.2019.00507. **(SCI)**.
6. Volgin AD, A Bashirzade, TG Amstislavskaya, OA Yakovlev, KA Demin, **YJ Ho,** D Wang, VA Shevyrin, D Yan, Z Tang, J Wang, M Wang, ET Alpyshov, N Serikuly, EA Wappler-Guzzetta, AM Lakstygal, AV Kalueff. Dark classics in chemical Neuroscience: arecoline. ***ACS Chem Neurosci***, 10(5): 2176-85, Jan. 2019. **(SCI)**
7. Lai CL, WM Chi, **YJ Ho**, CC Lin, HC Lin, CL Kuo, JH Chen* Using a Numerical Method to Precisely Evaluate the Alpha Angle in a Hip Image. ***Med Biol Eng Comput***, published online: 08 April, 2019. DOI: 10.1007/s11517-019-01973-4 **(SCI)**
8. Tai CH, M Bellesi, AC Chen, CL Lin, HH Li, PJ Lin, WC Liao, CS Hung*, RK Schwarting*, **YJ Ho***. A new avenue for treating neuronal diseases: ceftriaxone, an old antibiotic demonstrating behavioral neuronal effects. ***Brain Res Res*** 364: 149- 156, Feb. 20, 2019. **(SCI)**
9. **何應瑞***、許弘毅、張鳴宏、廖玟潔、林志立*、洪菁穗*。從路易氏體失智症之病理特徵找尋治療方法 (Exploring a therapeutic method for dementia with Lewy bodies based on the pathophysiology)。***台灣醫學雜誌*** 23(3): 376-83, 2019
10. **何應瑞***、沈枚萱、陳安芝、戴春暉、洪菁穗*、邱百誼*、賴德仁*。路易氏體失智症複雜的神經病理:頭孢曲松治療之潛力(Complicated pathophysiology of dementia with Lewy bodies: Therapeutic potential of ceftriaxone. ***Clinical Medicine*** 83(3): 185-93, 2019)。***臨床醫學雜誌*** 83(3): 185-93, 2019
11. Kung WM, **Ho YJ**, H Yoshizawa, S Matsuo, CY Wei. Behavioural and cognitive changes in Lewy body dementia. ***Behavioural Neurology***, vol. 2018, 2018. Article ID: 2404191, 2018. **(SCI)**
12. Chang CC, TC Lin, HL Ho, HH Li, CY Kuo, TA Korolenko, WJ Chen, TJ Lai, **YJ Ho***, CL Lin*. GLP-1 analogue Liraglutide attenuates mutant huntingtin-induced neurotoxicity by restoration of neuronal insulin signaling. ***Int J Mol Sci*** 19: 2505, 2018. **(SCI)**
13. **Ho YJ***, JC Weng, CL Lin, MS Shen, HH Li, WC Liao, NM Tsai, CS Hung*, TJ Lai*, IY Lee*. Ceftriaxone treatment for neuronal deficits: a histological and MEMRI study in a rat model of dementia with Lewy bodies. ***Behav Neurol*** 2018: 4618716, Aug. 2, 2018. **(SCI)**
14. Chang CC, HH Li, YT Chang, **YJ Ho**, LJ Hsieh, PY Chiu, YS Cheng, CL Lin, TJ Lai. Abeta exacerbates α-synuclein-induced neurotoxicity through impaired insulin signaling in α-synuclein-overexpressed human SK-N-MC neuronal cells. ***CNS Neuroscience & Therapeutics*** 24(1): 47-57, 2018. . DOI: 10.1111/cns.12772. Oct. 11, 2017. **(SCI)**
15. Chi WM, CC Lin, **YJ Ho**, HC Lin, JH Chen*. Using nonlinear finite element models to analyse stress

distribution during subluxation and torque required for dislocation of newly developed total hip structure after prosthetic impingement. ***Med Biol Eng Comput*** 56: 37- 47, 2018. **(SCI)**

16. Hsieh MH[#], WY Meng[#], WC Liao[#], JC Weng, HH Li, HL Su, CL Lin*, CS Hung*, **YJ Ho***. Ceftriaxone reverses deficits of behavior and neurogenesis in an MPTP-induced rat model of Parkinson's disease dementia. ***Brain Res Bull*** 132: 129- 38, 2017. **(SCI)**
17. Tikhonova MA, SC Ho, AA Akopyan, NG Kolosova, JC Weng, WY Meng, CL Lin, TG Amstislavskaya, **YJ Ho***. Neuroprotective effects of ceftriaxone treatment on cognitive and neuronal deficits in a rat model of accelerated senescence. ***Behav Brain Res***, 330: 8-16, May. 12, 2017. **(SCI)**
18. Chen LY, TY Renn, WC Liao, FD Mai, **YJ Ho**, G Hsiao, AW Lee, HM Chang. Melatonin successfully rescues hippocampal bioenergetics and improves cognitive function following drug intoxication by promoting Nrf2-ARE signaling activity. ***J Pineal Res*** e12417, May. 2, 2017. **(SCI)**
19. Weng JC, MA Tikhonova, JH Chen, MS Shen, WY Meng, YT Chang, KH Chen, KC Liang, CS Hung, TG Amstislavskaya, **YJ Ho***. Ceftriaxone prevents the neurodegeneration and decreased neurogenesis seen in a Parkinson's disease rat model: an immunohistochemical and MRI study. ***Behav Brain Res*** 305: 126-39, Mar 08, 2016 **(SCI)**
20. Lin CL, YS Cheng, HH Li, PY Chiu, YT Chang, **YJ Ho**, TJ Lai. Amyloid-β suppresses AMP-activated protein kinase (AMPK) signaling 2 and contributes to α-synuclein-induced cytotoxicity. ***Exp Neurol*** 275: 84-98, 2016. **(SCI)**
21. Chi WM, CY Wang, LY Chen, **YJ Ho**, PJ Wu, JH Chen. Effects of Yuan Ji dance on standing balance control in community-dwelling middle-aged and elderly people. ***J Nan Kai***, 12: 1, 21-30, 2015.
22. Huang CK, YT Chang, TG Amstislavskaya, MA Tikhonova, CL Lin, CS Hung, TJ Lai, **YJ Ho***. Synergistic effects of ceftriaxone and erythropoietin on neuronal and behavioral deficits in an MPTP-induced animal model of Parkinson's disease dementia. ***Behav Brain Res*** 294: 198-207, Aug 15, 2015. **(SCI)**
23. Tikhonova MA, AV Romaschenko, AE Akulov, **YJ Ho**, NG Kolosova, MP Moshkinb, TG Amstislavskaya. Comparative study of perception and processing of socially or sexually significant odor information in male rats with normal or accelerated senescence using fMRI. ***Behav Brain Res***. 294: 89-94, Aug. 12, 2015. **(SCI)**
24. Lin HC HC, WM Chi, **YJ Ho**, CC Lin, JH Chen. Theoretical Analysis of Total Hip Dislocation and Comparison of the Hemispherical Cup and a Newly Developed Cup. ***Med Biol Eng Comput*** 51(4): 397-404, Apr. 1, 2015. **(SCI, EI)**
25. Tikhonova MA, CH Ting, NG Kolosova, CY Hsu, JH Chen, CW Huang, GT Tseng, CS Hung, PFu Kao, TG Amstislavskaya, **YJ Ho***. Improving bone microarchitecture in aging with diosgenin treatment: a study in senescence-accelerated OXYS rats. ***Chin J Physiol*** 58(5): 322-31, Oct. 31, 2015 **(SCI)**
26. Hsu CY, CS Hung , HM Chang, WC Liao, SC Ho, **YJ Ho***. Ceftriaxone prevents and reverses behavioral and neuronal deficits in an MPTP-induced animal model of Parkinson's disease dementia. ***Neuropharmacol*** 91:43-56, 2015. **(SCI)**
27. Chu SC, PN Chen, **YJ Ho**, CH Yu, YS Hsieh, DY Kuo*. Both neuropeptide Y knockdown and Y1 receptor inhibition modulate CART-mediated appetite control. ***Hormones and Behavior*** 67: 38-47, 2015. **(SCI)**
28. Lin WL, SM Wang, **YJ Ho**, HC Kuo, YJ Lee, TH Tsen. Ethyl acetate extract of Wedelia chinensis inhibits tert-butyl hydroperoxide-induced damage in PC12 cells and D-galactose-induced neuronal cell loss in mice. ***BMC Complement Altern Med*** 14: 491, 2014. **(SCI)**
29. Ho SC, CC Hsu, CR Pawlak, MA Tikhonova, TJ Lai, TG Amstislavskaya, **YJ Ho***. Effects of ceftriaxone on the behavioral and neuronal changes in an MPTP-induced Parkinson's disease rat model. ***Behav Brain Res*** 268: 177-84, May 05, 2014. **(SCI)**
30. Ho SC, CC Hsu, CH Yu, WN Huang, MA Tikhonova, MC Ho, CS Hung, TG Amstislavskaya, **YJ Ho***. Measuring Attention in a Parkinson's disease Rat Model using the 5-arm Maze Test. ***Physiology & Behavior*** 130: 176-81, May 05, 2014. **(SCI)**

31. Tikhonova MA, CH Yu, NG Kolosova, LA Gerlinskaya, SO Maslennikova, AV Yudina, TG Amstislavskaya, **YJ Ho***. Comparison of behavioral and biochemical deficits in rats with hereditary defined or D-galactose-induced accelerated senescence: Evaluating the protective effects of diosgenin. ***Pharmacol Biochem and Behav*** 120: 7-16, Feb. 1, 2014. **(SCI)**

32. Hung YT, MA Tikhonova, SJ Ding, PF Kao, HHC Lan, JM Liao, JH Chen, TG Amstislavskaya, and **YJ Ho***. Effects of chronic treatment with diosgenin on bone loss in a D-galactose-induced aging rat model. ***Chin J Physiol*** 57(3): 121- 27, 2014. **(SCI)**.

33. Lin HC, WM Chi, **YJ Ho**, JH Chen. Effects of design parameters of total hip components on the impingement angle and determination of the preferred liner skirt shape with an adequate oscillation angle. ***Med Biol Eng Comput*** 51(4): 397- 404, Apr. 1, 2013. **(SCI)**

34. Yang LH, **YJ Ho**, JF Lin, CW Yeh, SH Kao, LiS Hsu. Butein inhibits the proliferation of breast cancer cells through generation of reactive oxygen species and modulation of ERK and p38 activities. ***Molecular medicine reports*** 6(5):1126-32, Nov. 2012. **(SCI)**

35. Hsia CH, CH Wang, YW Kuo, **YJ Ho**, HL Chen. Fructo-oligosaccharide systemically diminished D-galactose-induced oxidative molecule damages in BALB/cJ mice. ***British Journal of Nutrition*** 107: 1787–92, 2012. **(SCI)**.

36. Lin HC, WM Chi, **YJ Ho**, JH Chen*. Effects of design parameters of total hip components on the impingement angle and determination of the preferred liner skirt shape with an adequate oscillation angle. ***Med Biol Eng Comput*** 51(4): 397- 404, Apr. 1, 2013. **(SCI)**.

37. Hsia CH, CH Wang, YW Kuo, **YJ Ho**, HL Chen. Fructo-oligosaccharide systemically diminished D-galactose-induced oxidative molecule damages in BALB/cJ mice. ***British Journal of Nutrition*** 107: 1787–92, 2012. **(SCI)**.

38. Hsieh MH, SC Ho, KY Yeh, CR Pawlak, HM Chang, **YJ Ho***, TJ Lai*, FY Wu. Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson's disease rat model. ***Pharmacology, Biochemistry and Behavior*** 102: 64-71, 2012. **(SCI)**.

39. Pawlak CR, FS Chen, FY Wu, **YJ Ho***. Potential of D-cycloserine in the treatment of behavioral and neuroinflammatory disorders in Parkinson's disease and studies that need to be performed before clinical trials. ***Kaohsiung J Med Sci*** 28(8): 407-17, Aug. 16, 2012. **(SCI)**.

40. **Ho YJ***, FL Chen, SM Liu, AL Wang, YC Li, TJ Lai, SS Huang. Effects of chronic resistive airway loading on behavioral changes in rats. ***Chin J Physiol*** 55(4): 245-252, Aug. 31, 2012. DOI: 10.4077/CJP.2012.BAA044 **(SCI)**.

41. **Ho YJ***, SY Tai, CR Pawlak, AL Wang, CW Cheng, MH Hsieh. Behavioral and IL-2 Responses to Diosgenin in Ovariectomized Rats. ***Chin J Physiol*** 55(2): 91-100, 12 Apr, 2012. **(SCI)**.

42. Pawlak CR, BD Karrenbauer, P Schneider, **YJ Ho**. The elevated plus-maze test: differential psychopharmacology of anxiety-elated behavior. ***Emotion Review*** 4(1):98-115, Jan. 24, 2012. **(SCI)**

43. Hsieh MH, SL Gu, SC Ho, CR Pawlak, CL Lin, **YJ Ho***, TJ Lai, FY Wu. Effects of MK-801 on recognition and neurodegeneration in MPTP-induced Parkinson's rat model. ***Behav Brain Res*** 229(1): 41-47, Jan. 10, 2012 **(SCI)**

44. Schneider P, WF Wolfgang, N Schweinfurth, **YJ Ho**, A Sartorius, R Spanagel, CR Pawlak. Central metabolite changes and activation of microglia after peripheral interleukin-2 challenge. ***Brain Behav Immun***, 26(2): 277-83, Feb. 1, 2012. **(SCI)**

45. Chang CC, TC Kuan, YY Hsieh, **YJ Ho**, YL Sun, CS Lin. Effects of diosgenin on myometrial matrix metalloproteinase-2 and -9 activity and expression in ovariectomized rats. ***Int J Biol Sci*** **7**: 837-847, July. 7. 2011. **(SCI)**

46. Schneider P, **YJ Ho**, R Spanagel, CR Pawlak. A novel elevated plus-maze procedure to avoid the one-trial tolerance problem. ***Frontiers in Behavioral Neuroscience*** 5(43):1-8, July 27, 2011. **(SCI)**

47. **Ho YJ***, SC Ho, CR Pawlak, KY Yeh. Effects of D-cycloserine on MPTP-induced behavioral and neurological changes: potential for treatment of Parkinson's disease dementia**.** ***Behavioural Brain Research*** 219(2): 280-90, 2011. **(SCI)**

48. Huang GJ, SC Ho, CK Lai, SL Gu, MH Hsieh, **YJ Ho***. D-cycloserine reverses recognition deficits in MPTP-induced Parkinson's disease mice model. ***Proceedings of XVII International Congress of Neuropathology***, pp 31-35, 2010. (September 11-15, 2010, Salzburg, Austria)

49. Ho SC, GJ Huang, CK Lai, SL Gu, MH Hsieh, **Ho YJ***. MPTP-induced animal model of Parkinson's disease dementia: there are species differences. ***Proceedings of XVII International Congress of Neuropathology*** pp 23-29, 2010. (September 11-15, 2010, Salzburg, Austria)

50. Sy HN, SL Wu, WF Wang, CH Chen, YT Huang, YM Liou, CS Chiou, CR Pawlak, **YJ Ho***. MPTP-induced dopaminergic degeneration and deficits in object recognition in rats are accompanied by neuroinflammation in the hippocampus. ***Pharmacol Biochem and Behav*** 95:158-165, Feb. 26, 2010. **(SCI)**.

51. Wang AL, YM Liou, CR Pawlak, **YJ Ho***. Involvement of NMDA receptors in both MPTP-induced neuroinflammation and deficits in episodic-like memory in Wistar rats. ***Behav Brain Res*** 208: 38-46, Mar. 17th, 2010. **(SCI).**

52. Wang WF, SL Wu, YM Liou, AL Wang, CR Pawlak, **YJ Ho***. MPTP lesion causes neuroinflammation and deficits in object recognition in Wistar rats. ***Behavioral Neuroscience*** 123(6): 1261-70, Dec. 17th, 2009. **(SCI)**.

53. Karrenbauer BD, **YJ Ho**, V Ludwig, J Löhn, R Spanagel, RKW Schwarting, CR Pawlak. Time-dependent effects of striatal interleukin-2 on open field behaviour in rats. ***Journal of Neuroimmunology*** 208: 10-18, Mar. 31, 2009. **(SCI)**.

54. Bauhofer A, **YJ Ho**, A Schmitt, M Köster, RKW Schwarting, CR Pawlak. Individual behavioral differences in recovery from abdominal sepsis in rats. ***Inflammation Research*** 58:1-9, Feb. 5, 2009. **(SCI)**.

55. Lee SD, WW Kuo, **YJ Ho**, AC Lin, CH Tsai, HF Wang, CH Kuo, AL Yang, CY Huang, JM Hwang. Cardiac Fas-dependent and mitochondrial dependent apoptosis in ovariectomized rats. ***Maturitas*** 61:268-77, Nov. 20, 2008. **(SCI).**

56. Chiang CY, KY Yeh, SF Lin, H Hsuchou, MY Tai, **YJ Ho***, YF Tsai. Effects of alcohol on the mouse-killing behavior of olfactory bulbectomized rats. ***Chinese Journal of Physiology*** 51(6): 408-13, Dec. 31, 2008. **(SCI)**

57. Chen JH, JSS Wu, HC Lin, SL Wu , WF Wang, SK Huang, **YJ Ho***. Dioscorea improves the morphometric and mechanical properties of bone in ovariectomized rats**.** ***Journal of the Science of Food and Agriculture*** 88: 2700-06, Oct. 7. 2008. **(SCI)**

58. Pawlak CR*, **YJ Ho***, R. K.W. Schwarting*. Animal models of human psychopathology based on individual differences in novelty-seeking and anxiety. ***Neuroscience & Biobehavioral Reviews*** 32: 1544-68, Oct. 10. 2008. **(SCI)**

59. Lee YT, WF Wang, CW Cheng, SL Wu, CR Pawlak, **YJ Ho***. Effects of escapable and inescapable stressors on behavior and interleukin-2 in the brain. ***Neuroreport*** 19(12): 1243-47, Aug. 6. 2008. **(SCI)**

60. Hsieh YS, SF Yang, SC Chu, **YJ Ho**, CS Kuo, DY Kuo. Transcriptional interruption of cAMP response element binding protein modulates superoxide dismutase and neuropeptide Y-mediated feeding behavior in freely moving rats. ***Journal of Neurochemistry*** 105: 1438-1449, May. 2008. **(SCI)**

61. Wu SL, LS Hsu, WT Tu, WF Wang, YT Huang, CR Pawlak*, **YJ Ho***. Effects of D-cycloserine on the behavior and ERK activity in the amygdala: Role of individual anxiety levels. ***Behavioral Brain Research*** 187(2): 246-53, Mar. 5. 2008. **(SCI)**

62. **Ho YJ***, WY Hsu, CF Wang, T Tseng, CW Cheng, YC Hung, CC Hsu, MD Kao, YF Tsai. Psychoimmunological effects of dioscorea in the ovariectomized rats: role of anxiety level. ***Annals of General Psychiatry*** 6:21, Aug. 10, 2007.

63. Wang WF, YP Lei, T Tseng, WY Hsu, CF Wang, CC Hsu, **YJ Ho***. Effects of apomorphine on the expression of learned helplessness behavior. ***Chinese Journal of Physiology*** 50(2): 63-68, Apr. 30, 2007. **(SCI).**

64. Chen LM, WW Kuo, JJ Yang, SG Wang, YL Yeh, FJ Tsai, **YJ Ho**, MH Chang, CY Huang, SD Lee.

Eccentric cardiac hypertrophy was induced by long-term intermittent hypoxia. ***Experimental Physiology*** 92(2):409-16 Mar. 2007. **(SCI).**

65. **Ho YJ***, LS Hsu, CF Wang, WY Hsu, TJ Lai, CC Hsu, YF Tsai. Behavioral effects of D-cycloserine in rats: the role of anxiety level. ***Brain Res*** 1043: 179-185, May. 2005. **(SCI)**.
66. **Ho YJ**, KH Chen, MY Tai, YF Tsai. MK-801 suppresses muricidal behavior but not locomotion in olfactory bulbectomized rats: involvement of NMDA receptors. ***Pharmacol Biochem Behav*** 77: 641-46, Mar. 2004. **(SCI)**.
67. **Ho YJ**, H Hsuchou, HA Shui, MY Tai, KH Chen, YF Tsai. Effects of desipramine and MK-801 on components of muricidal behavior in olfactory bulbectomized rats: an application of incisor-cutting animal model. ***Neurosci Res Comm*** 34(3): 136-43, May. 2004. **(SCI)**.
68. **Ho YJ**, CR Pawlak, LH Ku, RKW Schwarting. Acute and long-term consequences of single MDMA administration in relation to individual anxiety levels in the rat. ***Behav Brain Res*** 149: 135-44, Mar. 2004. **(SCI).**
69. Pawlak CR, **YJ Ho**, RKW Schwarting, A Bauhofer. Relationship between striatal levels of interleukin-2 mRNA and plus-maze behaviour in the rat. ***Neurosci Lett*** 341: 205-08, May. 2003. **(SCI).**
70. **Ho YJ**, J Eichendorff, RKW Schwarting. Individual response profiles of male Wistar rats in animal models of anxiety and depression. ***Behav Brain Res*** 136: 1-12, Oct. 2002. **(SCI)**.
71. Hsuchou H, **YJ Ho**, HA Shui, MY Tai, KH Chen, YF Tsai. Effects of incisor cutting on muricidal behavior induced by olfactory bulbectomy in rats. ***Physiol and Behav*** 76 (4-5): 669-75, Aug. 2002. **(SCI)**.
72. **Ho YJ**, TM Liu, MY Tai, CS Wong, YF Tsai. Effects of olfactory bulbectomy on the density of NMDA receptors in rat's brain: [^{3}H] MK-801 binding assay. ***Brain Res*** 900: 214-18, May. 11, 2001. **(SCI)**
73. **Ho YJ**, YC Chang, TM Liu, MY Tai, CS Wong, YF Tsai. Striatal glutamate release during novelty exposure-induced hyperactivity in olfactory bulbectomized rats. ***Neurosci Lett*** 287 (2): 117-20, Jun. 23, 2000. **(SCI)**

(B) In Chinese with English Abstract

1. 何應瑞*、沈枚萱、陳安芝、戴春暉、洪菁穗*、邱百誼*、賴德仁*。路易氏體失智症複雜的神經病理:頭孢曲松治療之潛力(Complicated Pathophysiology of Dementia with Lewy Bodies: Therapeutic Potential of Ceftriaxone)。***臨床醫學雜誌*** (in press, 2018)。
2. 何應瑞*、許弘毅、張鳴宏、廖玟潔、林志立*、洪菁穗*。從路易氏體失智症之病理特徵找尋治療方法(Exploring a Therapeutic Method for Dementia with Lewy Bodies based on the Pathophysiology)。***台灣醫學雜誌*** (in press, 2018)。
3. **何應瑞***、許兆畬、陳福士、洪菁穗、賴德仁。紅血球生成素之神經保護效果：應用於治療巴金森氏症失智為例。澄清醫護管理雜誌 11(3): 37-42, Jul, 2015. (Neuronal protection of erythropoietin: a possible application in Parkinson's disease dementia. Cheng Ching Medical Journal 11(3): 37-42, Jul, 2015)
4. 廖丹瑜、洪櫻慈、周璟言、黃冠達、何詩君、黃國洲、張思毅、徐詩惠、吳聲輝、廖娟妙*、**何應瑞*** 。增加麩胺酸轉運子之表現對巴金森氏症大鼠的認知缺陷之效果。中華民國生醫材料及藥物致放學會 2012 年會論文集，Apr., 2012, Taipei。【Liao TY, YT Hung, CY Chou, GD Huang, SH Ho, GJ Huang, SY Chang, SH Hsu, SH Wu, JM Liao, **YJ Ho***. Effects of enhancing glutamate transporter expression on cognitive dysfunction in Parkinson's disease rat model. Biomaterials and Drug Delivery Systems 2012 Annual Meeting and Symposium, Apr., 2012, Taipei.】
5. 陳福士、黃國洲、吳富英、**何應瑞***。Amantadine 抑制巴金森氏症失智及 NMDA 受體於其中所扮

演之角色：文獻回顧與探討。***臨床醫學*** 68(5): 386-92, Nov. 1, 2011。

6. 莊婷、謝明鴻、陳福士、吳富英、**何應瑞***。**D-cycloserine** 加強暴露療法治療恐懼症之文獻回顧。***台灣醫學*** 15(6): 1-11, Jun 21, 2011. 。【Chuang T, MH Hsieh, FS Chen, FY Wu, **YJ Ho***. D-cycloserine facilitates the effects of exposure therapy on phobias. ***Formosan J Medicine*** 15(6): 1-11, Jun 21, 2011. (in Chinese with English abstract).】

7. **何應瑞***、巫錫霖、王文甫、施曉雅、黃耀庭。巴金森氏症患者的幻覺及其可能的神經心理機轉。***台灣醫學*** 14(1): 88-96, Jan. 1st, 2010。【**YJ Ho***, Wu SY, Wang WF, Sy HN, Huang YT. Hallucinations in Parkinson's disease: the possible neuropsychological mechanisms, *Formosan J Medicine* 14(1): 88-96, Jan. 1st, 2010. (in Chinese with English abstract).】

8. **何應瑞***、巫錫霖、王文甫、黃耀庭、鄭鈞文。麩胺酸神經系統與神經免疫功能在巴金森氏症失智的可能角色。***台灣醫學*** 13(1): 100-06, Jan. 1st. 2009。(CCH grant 93118 and 92521; NSC 96-2320-B-040-019)【**Ying-Jui Ho***, Shey-Lin Wu, Wen-Fu Wang, Yao-Ting Huang, Chun-Wen Cheng. Role of glutamatergic and neuroimmunological function in the dementia in Parkinson's disease. *Formosan J Medicine* 13(1): 100-06, Jan. 1st. 2009】

9. 王慶福、游顯妹、王郁茗、**何應瑞**、曾淑梅。配合生理回饋之放鬆訓練對重症加護病房護理人員焦慮反應之影響效果【The effects of biofeedback-assisted relaxation on nursing staffs with anxiety reaction in ICU, Chung Shan Medical Journal】。***中山醫學雜誌***，18(2): 241-53, Dec. 2007。

10. 王慶福、鍾麗珍、王郁茗、**何應瑞**、賴德仁。生理回饋訓練與放鬆訓練對大學生焦慮與憂鬱反應之影響效果 (Effect of biofeedback training and relaxation training on anxiety and depressive reactions of college students, Chung Shan Medical Journal）。***中山醫學雜誌***，18(2): 255-70, Dec. 2007。

11. 黃秋谷、王慶福、徐文鈺、**何應瑞***、黃耀庭、賴德仁。影響神經功能並參與情感疾病之發炎物質：心理神經免疫學之基礎。***臨床醫學月刊*** 58(1):51-56, Jul. 2006。【Huang CK, CF Wang, WY Hsu, YT Huang, TJ Lai, **YJ Ho***. Inflammatory substances affecting neuronal function and affective disorders: fundamentals of psychoneuroimmunology. ***Clinical Medicine*** 58(1): 51-56, Jul. 2006. (in Chinese with English abstract)】

12. **何應瑞***、蔡元奮。麩胺酸神經系統在憂鬱症中可能的角色：以嗅球被切除之大鼠為動物模式所得的證據。***台灣精神醫學雜誌*** 19(1): 5-18, Mar. 2005. **(TSSCI)**. 【**YJ Ho***, YF Tsai. Possible Role of Glutamatergic System in Depression: Evidence from Animal Model of Olfactory Bulbectomized Rats. ***Taiwanese J Psych*** 19(1): 5-18, Mar. 2005.】

13. 杜瑋庭、曾鼎、王安莉、鍾宛玲、林俊成、許立松、徐文鈺、王慶福、**何應瑞***。NMDA 受體在 D-cycloserine 對焦慮行為作用之角色。***台灣醫學*** 9(2): 173-179, Mar. 2005.【Tu WT, T Tseng, AL Wang, WL Chung, CC Lin, LS Hsu, WY Hsu, CF Wang, **YJ Ho**. Effects of D-cycloserine on anxiety behavior: role of NMDA receptor. ***Formosan Journal of Medicine*** 9(2): 173-197, Mar. 2005.) (in Chinese with English abstract)】

14. 黃秋谷、王慶福、徐文鈺、賴德仁、**何應瑞***。麩胺酸神經系統 NMDA 受體在精神分裂症之角色：作用在甘胺酸結合位之藥物所得的證據。***臨床醫學月刊*** 55(4): 253-258, Apr. 2005.【Huang CK, CF Wang, WY Hsu, TJ Lai, **YJ Ho***. Role of glutamatergic NMDA receptor in schizophrenia: evidence from drugs acting at the glycine binding site. ***Clinical Medicine*** 55(4): 253-258, Apr. 2005. (in Chinese with English abstract)】

15. 黃秋谷、**何應瑞***。搖頭丸：危險的急性中毒與棘手的慢性中毒。***臨床藥學雜誌*** 10 (2): 49-62, 2002. (Huang CK, **YJ Ho***. "Ecstasy", its dangerous acute-effects and long-term toxicity. ***Formosa J Clinic Pharmacy*** 10 (2): 49-62, 2002. (in Chinese with English abstract))

16. **何應瑞***。山藥，植物性的賀爾蒙。常春月刊 164:90-93, 1996。【**Ho YJ**. Dioscorea, Phytohormone. Evergreen 164:90-93, 1996. (in Chinese with English abstract)】

(C) Conference Abstract

More than **170** conference abstracts, since 1995.

(D) Patent

	Inventor/ Applicant	Title	Nation	No./Term	Note
1	發明人：何應瑞、陳建宏。申請人：中山醫大、江文舜	包含紅血球生成素及頭孢曲松的巴金森氏症失智用組合物 <併用 CEF+EPO PDD>	Korea	第 10-1971318 號 (2019.04.16-2036.04.21)	
2	Ho YJ/ 百朗克公司	頭孢曲松的用途: 治療路易氏體失智症<DLB>	Taiwan	I644673 (20181221-20370726)	公開號: TWI644673B
3	Ho YJ/ 百朗克公司 BrainX corporation	Use of ceftriaxone to treat dementia with Lewy bodies <DLB>	Canada		No. 87227-5CAM RW 200123
4	Ho YJ/ 百朗克公司 BrainX corporation	Use of ceftriaxone to treat dementia with Lewy bodies <DLB>	Japan	特許出願の番号: 特願 2018-095185	200207
5	Ho YJ, Chen JH/ CSMU, Vincent Chin	A Pharmaceutical Composition Comprising Erythropoietin and Ceftriaxone and A Use Thereof in the Manufacture of a Medicament for the Treatment of Parkinson's Disease Dementia <併用 CEF+EPO PDD>	Europe (German, France, Great Britain, Poland,)	EP3085383 (20181128-20360420) 波蘭: PL3085383T3 西班牙: ES2714123T3 土耳其: TR201902863T4	公開號: EP3085383B1
6	何應瑞、陳建宏/中山醫大、江文舜	使用一包含有頭孢曲松與紅血球生成素的組合來治療和/或預防巴金森氏症失智 <併用 CEF+EPO PDD>	Taiwan	I558410 (201611- 203504)	公開號: TWI558410B
7	Ho YJ, Chen JH/ CSMU, Vincent Chin	使用頭孢曲松來治療和/或預防巴金森氏症失智 (Treatment and / or prevention of Parkinson's disease dementia with ceftriaxone)	USA	US 9,326,988 B2 (20130313-20330312?)	公開號: US09326988B2
8	何應瑞、陳建宏/中山醫大、江文舜	用头孢曲松制备治疗和/或预防帕金森氏症失智的医药品的用途 Applications of medicine prepared from ceftriaxone and used for curing and/or preventing dementia caused by Parkinson's disease	China	ZL201210154964.2 (201205- 203205)	公開號: CN103417547B
9	Ho YJ, Chen JH/ CSMU, Vincent Chin	A use of pharmaceutical composition comprising erythropoietin and ceftriaxone in the manufacture of a medicament for the treatment of Parkinson's disease dementia <併用 CEF+EPO PDD>	Australia	AU2016202491B2 104112897 (20160420-20360419)	公開號: AU2016202491B2
10	Ho YJ, Chen JH/ CSMU, Vincent Chin	A use of pharmaceutical composition comprising erythropoietin and ceftriaxone in the manufacture of a medicament for the treatment of Parkinson's disease dementia <併用 CEF+EPO PDD>	Japan	特許第 6298490 號 (20160420-20360419)	公開號: JP6298490B2
11	何應瑞 /何應瑞、中山醫大	用於治療神經退化性疾病之醫藥組合物 (Pharmaceutical compositions for treatment of	Taiwan	I544923 (201608- 202912)	公開號: TWI544923B

		neurodegenerative disorders) <**DCS** PDD>			
12	陳建宏、何應瑞 /中山醫學大學	全人工髖關節結構(Total hip structure)	Taiwan	I546063 (201502- 203602)	公開號: TWI546063B
13	何應瑞 / 鴻剛實業股份有限公司	動物注意力訓練及測量裝置 (Instrument for measuring and training animal attention)	Taiwan	M433088 (201206- 202202)	公開號: TWM433088U
14	何應瑞、陳建宏 /中山醫學大學、何應瑞、晉亞化工廠	使用薯蕷皂素來改善停經症候群有關聯的認知缺陷	China	ZL 201110100440.0 (201306- 203305)	公開號: CN102462692B
15	何應瑞、陳建宏 /中山醫學大學	使用薯蕷皂素來改善與停經期症候群有關聯的認知缺陷（Improvement of cognitive deficit Associated with Menopausal syndrome with diosgene）	Taiwan	I422378 (201401- 203412)	公開號: TWI422378B

(E) Book

1. 人體生理學：身體功能之機轉。賴義隆、何應瑞等譯自 Vander, Sherman, Luciano's Brief Edition Human Physiology。2006 年，藝軒圖書出版社。（ISBN：986157252X）
2. 王春美、何應瑞、施柯念、秦作威、高婷玉、溫小娟、葉睿毅、廖美華、滿庭芳、駱明潔、盧敏吉、顏惠芷。新編生理學。華格那企業有限公司，2004 年，台中市。(ISBN 986-7905-27-X)

   Ho YJ. (2003). Nervous system. In CM Chung (Eds.): *Current Physiology*. Wagner Publishing Co. Ltd., Tai-Chung, Taiwan. 77-120. (ISBN 986-7905-27-X)

   Ho YJ. (2003). The central nervous system. In CM Chung (Eds.): *Current Physiology*. Wagner Publishing Co. Ltd., Tai-Chung, Taiwan. 121-148. (ISBN 986-7905-27-X)
3. 吳莉玲、朱冠州、何應瑞。生理學精要。藝軒圖書出版社，2003 年，台北市。(ISBN 9576167108)
4. 吳莉玲、何應瑞。生理學精華。藝軒圖書出版社，2002 年，台北市。(ISBN 9576166799)

PROFESSIONAL MEMBERSHIPS

Taiwan Neuromodulation Society
Taiwanese Psychological Association
Society for Neuroscience
The Chinese Physiological Society
The Chinese Neuroscience Society

LICENCE

Pharmacist of ROC

證照：專門職業及技術人員高等考試藥師藥字第 17091 號

HONOR AND AWARDS

2016 Special Talents Award (MOST, ROC. 2016.08.01- 2017.07.31)
2015 Special Talents Award (MOST, ROC. 2015.08.01- 2016.07.31)
2014 Special Talents Award (MOST, ROC. 2014.08.01- 2015.07.31)
2014 Super Teacher Award (Teachers Union of Taichung, ROC. 2015)
2013 Outstanding Teaching Award, Chung Shan Medical University
2013 Special Talents Award, National Science Consul (NSC, ROC. 2013.08.01- 2014.07.31)
2012 Special Talents Award, National Science Consul (NSC, ROC. 2012.08.01- 2013.07.31)
2005 Aristotle Research Award, The International Society on Brain and Behaviour, Europ
2003 Award of Outstanding Scientific Achievement and Presentation, Neuroscience Society, ROC
2001 Visiting Scholar of NSC and DAAD, Germany
2000 Award of Scholarship from Chung Hwa Rotary Educational Foundation, ROC
1993 Award of Scholarship from Academic Research Foundation, ROC

UNIVERSITY COMMITTEES

Interviewer, Department of Psychology applicants, Chung Shan Medical University (2002-present)
Committee on Faculty Promotions and Evaluation, School of Psychology, Chung Shan Medical University (2002-present)
Committee on Faculty Promotions and Evaluation, School of Optometry, Chung Shan Medical University (2002-present)
Committees, Environment and Safety Office, Chung Shan Medical University (2002-present)

MAILING ADDRESS:

Ying-Jui Ho Ph.D. Professor

Department of Psychology, Chung Shan Medical University
Address: No.110, Sec.1, Jianguo N. Rd., Taichung City 402, Taiwan, ROC
Tel: +886-4-24730022#11673
Fax: +886-4-23248191
E-mail: yjho@csmu.edu.tw; joshuayjho@gmail.com